CoreVitals targets the next frontier in preventative health

We’re in a pivotal moment for consumer-led health. There’s an increasing demand for personalised care, data-driven insights, and a surging interest in longevity and preventative health, driven by both scientific advances and shifting consumer priorities. Consumers are taking a more active role in understanding and optimising their wellbeing, often independent of traditional public healthcare pathways.

CoreVitals is a London-based health tech startup that’s reimagining proactive healthcare through deep diagnostics and personalised insights. It combines over 100 blood biomarkers across health parameters such as cardiovascular, liver, kidney, hormone, nutritional, immune and metabolic health with expert interpretation and digital delivery to support improvements in longevity, energy, and performance. 

I spoke to Millie O'Brien, Head of Growth at CoreVitals, to learn more.

CoreVitals aims to make functional medicine-level care more accessible and action-oriented, with a goal of enabling one million people to actively manage their long-term health by 2030.

CoreVitals was founded by two visionaries. Serial entrepreneur Adil Mohammed, whose previous ventures include Launch48, acquired by Oxygen Accelerator in 2012, and Fabrily, acquired by Teespring in 2015. Dr Nitin Shori is a 20+ years GP and was the medical director of Pharmacy2U, who were the biggest online pharmacy in the UK and a pioneer in the provision of telehealth in the UK.

In February 2024, they launched GetScanned, a diagnostics platform competing directly with Scan.com in the UK. It expanded to Premium subscription service company Elevate, which launched in January this year.  Following strong consumer interest, the team decided to launch Corevitals, which is based on the same proactive healthcare philosophy, but at a lower price point, focused on tracking blood biomarkers over time.

CoreVitals rejects the one-off blood test model dominating the UK market

In the current UK market, most blood test competitors offer “build your own” one-off tests.  According to O’Brien, “People pick what to test based on past experiences or biases — say you had anaemia 15 years ago, you might test for iron. But what if the real issue now is hormonal? You might not test for that at all.”

“We wanted to avoid that bias. So our panel was designed by GPs and covers everything from early cancer detection to hormonal health, nutrients, and more.”

CoreVitals members receive two in-depth blood tests annually, beginning with a comprehensive overview of all body systems. This is followed by a second test designed to monitor changes and progress in key markers that fluctuate more frequently, such as lipid profiles, heart health, iron, and vitamin D. 

I was curious how this works for factors that may change more often, like hormones. CoreVitals is already building functionality into version 2 of its product to allow for additional testing options and increased testing frequency, especially for those tracking specific conditions.

From NHS bottlenecks to real-time results

A persistent painpoint I see in healthtech is to get adoption for digital platform data from local doctors and health providers. 

To address this, CoreVitals works with one of the most trusted labs in the UK to create foundational credibility. 

O’Brien contends that “ordering tests through the NHS is already a nightmare. Most private GPs already use labs like Randox Health."

"A nutritionist I spoke to recently was trying to get hormonal tests done for a client. The NHS setup was complicated and expensive when pieced together. It’s just not built to be modular or flexible.”

The company has also started a direct-to-consumer (D2C) approach to get early insights and iterate on the product.  It's also fast-tracking a B2B2C offering for:

• Functional medicine professionals,
• Nutritionists,
• Fertility experts,
• GPs who want admin dashboards and integration with results

According to O Brien, this would allow them to refer patients, access results directly, and have a real-time interface rather than relying on patients to email a PDF. 

Women’s health to Parkinson’s: innovation spreads across preventative healthtech

Data-driven personalised healthtech is a sector that’s experiencing increased startup innovation and growing investor appetite, with examples including  Vivian Lab and Solence (women’s health and Kois Care (Parkinson's).

In January, Swiss preventative health company Neko Health raised $260 million in a Series B round to expand its AI-powered, non‑invasive full‑body health scan — which maps millions of data points in under an hour and includes a doctor consultation 

Then in June, Swiss company Aeon raised €8.2 million in Seed funding for its platform that uses MRI, advanced biomarkers, and genetic insights to enable early detection and prediction of over 500 diseases in a single check-up.

Last month, UK digital healthtech Numan raised $60 million, bringing its funding to over $130 million. 

O’Brien contends that “CoreVitals stands out from a product like NekoHealth because their so-called ‘full body scan’ is observational rather than comprehensive, their blood tests are very basic, and it’s ultimately an in-clinic, one-time experience.” 

CoreVitals aims to offer a long-term health relationship. 

“Our tests are actionable, with regular tracking and personalisation. We’re also building a strong clinical team and advisory board to support the product with medical depth, not just visuals, and real support.”

This includes 1:1 nutritionist support and functionality to chat with doctors and nutritionists in their app. Further, CoreVitals wants to serve a broad population not just wealthy early adopters or tech bros. O’Brien admits that most medical research is skewed.

“Women and minorities are massively underrepresented. We’ve had strong early interest from women, especially in hormonal and metabolic categories."

Crucially, the platform also offers access to less common diagnostics such as:

• Detailed lipid profiles, especially for people managing pre-diabetes or coming off GLP-1 drugs.
• Comprehensive inflammation marker testing, which can help detect early signs of chronic disease
• Extensive women's and men's hormone panels

Thousands of people have signed up for waitlisting, with the platform already being tested by a small cohort with good results.  But according to O'Brien, the key challenges so far are messaging and education. 

“There’s a lot of “woo” in the space. People want to be healthier, but they often struggle to understand what that means in practical terms. So we’re using condition-specific messaging:

“Got PCOS? Here’s how Corevitals can help.

“In your 40s and feeling tired? Let’s talk testosterone."

As its early days for the company, it lacks the kind of native user data that can drive insights across the platform, so its exploring how to incorporate large public datasets available for medical research. 

Thus for its first few hundred users, a GP will manually review every result from CoreVitals platform to validate the clinical accuracy of its automated insights.

As it scales, the company aims to bridge the gap between advanced testing and everyday healthcare, making personalised, data-driven health management a reality for a wider population.